XANOMELINE

SynDRA canonical compound SYN0001248 — structure-anchored drug synonym record

Clinical phase	Phase 3
Primary target(s)	CHRM1 \| CHRM2 \| CHRM3 \| CHRM4 \| CHRM5 \| HTR1A \| HTR1B \| HTR1D \| HTR1E \| HTR1F \| HTR2A \| HTR2B \| HTR2C \| HTR6 \| HTR7
Mechanism of action	acetylcholine receptor agonist

All known targets

LY246708
xanomeline tartrate
LY-246708
Xanomelina
LY-246708 FREE BASE
Xanomeline tartrate
Memcor
Xanomeline tartrate [USAN]
LY 246708 tartrate
Xanomeline tartrate (USAN)
Pyridine, 3-(4-(hexyloxy0-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (2R,3R)-2,3-dihydroxybutanedioate (1:1)
Pyridine, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-, (R-(R*,R*))-2,3-dihydroxybutanedioate (1:1)
3-(4-(Hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine L-(+)-tartrate (1:1)
3-hexoxy-4-(1-methyl-3,6-dihydro-2H-pyridin-5-yl)-1,2,5-thiadiazole
3-(Hexyloxy)-4-(1-methyl-1,2,5,6-tetrahydropyridin-3-yl)-1,2,5-thiadiazole
9ORI6L73CJ
CHEMBL21536
5-(4-HEXYLOXY-[1,2,5]THIADIAZOL-3-YL)-1-METHYL-1,2,3,6-TETRAHYDRO-PYRIDINE
CHEBI:10056
5-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1-methyl-1,2,3,6-tetrahydropyridine
Xanomeline (USAN)
MFCD00867179
XANOMELINE [USAN]
Pyridine, 3-(4-(hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methyl-
Xanomeline [USAN:INN]
UNII-9ORI6L73CJ
Lumeron
Hexyloxy-TZTP
Pyridine, 3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methyl-
XANOMELINE [MI]
XANOMELINE [INN]
GTPL57
3-(4-(Hexyloxy)-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine
XANOMELINE [MART.]
XANOMELINE [WHO-DD]
SCHEMBL121046
DTXSID60157286